View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 7, 2021

EMA CHMP recommends granting approval for Roche’s therapy to treat Covid-19

The advice is based on data from trials where Actemra/RoActemra lowered death risk in severe or critical Covid-19 patients.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended EU marketing authorisation for Roche’s Actemra/RoActemra (tocilizumab) to treat adult Covid-19 patients.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

If approved, the treatment is intended for patients who are taking systemic corticosteroids and need supplemental oxygen. These individuals also require mechanical ventilation.

An anti-interleukin 6 (IL-6) receptor biologic, Actemra/RoActemra is offered in intravenous as well as subcutaneous formulations to treat adults with moderate-to-severe active rheumatoid arthritis.

The European Commission will decide on the approval of Actemra/RoActemra soon.

The CHMP commenced an expedited analysis of the therapy in August this year and reviewed data from four clinical trials that enrolled more than 5,500 severe or critical Covid-19 patients.

Data from Phase III COVACTA, EMPACTA and REMDACTA trials led by Roche and the company-supported RECOVERY trial by the University of Oxford in the UK were analysed by the committee.

The totality of the clinical data showed that Actemra/RoActemra lowered mortality risk in individuals with severe or critical disease.

Roche Global Product Development head and chief medical officer Levi Garraway said: “As Covid-19 cases in Europe rise and with pressure on hospitals likely to increase, the need for effective treatments for those suffering most severely with Covid-19 could intensify.

“We are proud that the CHMP has recognised the potential of Actemra/RoActemra as we continue our efforts to bring treatment options to those most in need.”

Actemra/RoActemra received emergency use authorization in the US and Ghana, provisional approval in Australia and is also recommended by the World Health Organization (WHO) to treat Covid-19.

In September this year, Indian company Hetero received emergency use approval from the Drugs Controller General of India to manufacture a generic version of tocilizumab.

In a separate development, Roche concluded the repurchase of 53.3 million bearer shares of the company from Novartis for $20.7bn.

Roche announced repurchase plans in November this year.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology